MBII - Earnings call transcript Q2 2019 | Marrone Bio Innovations Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to today’s Marrone Bio Innovations’ Second Quarter 2019 Earnings Conference Call.

Just as a reminder, today’s call is being recorded.

At this time, I would like to turn the conference over to your host for today, Linda Moore, General Counsel. Please go ahead.

Linda Moore

Good afternoon, everyone, and thank you for joining our call. second conference XXXX Bio for the Innovations. to quarter call earnings Marrone Welcome

today Marrone; CEO, Jim the are On call Pam Chief Officer, Boyd; Commercial President Kevin Hammill. and CFO, and

I effects are characterizations statements. uncertainties, expressed will please as no projections, to statements that would or assurance be circumstances. implied well on conference some contain beliefs, different as beyond expectations, may management’s of forecasts of current on number or other expectations Such that regarding call company management can to materially from Such that regarding those intentions you a If or the anticipated. this which that Slide results X. has strategies are future affecting the remind management’s actual company. would or events may cause those refer statements performance these control, based beliefs and There you management’s and hopes, other future concerning future assumptions statements be or risks their like the be to future potential or and involve developments of by developments

company’s this obligation including any reflect revise with those are after discussed or events Securities disclaims factors to the management that guidance arise in earnings of The a this in may Form prove risks respects of or on could statements other should may conference year by guidance from the to vary any point-in-time represents that Should management’s forward-looking XXXX the expressly and materialize the Factors, or estimate. actual ended results circumstances website. update company Any date the call elsewhere or heading company uncertainties one assumptions or may the release Important or any and offer reports our company’s in that incorrect, today. material Exchange filed in contained annual report Risk call. differences cause more posted Commission, of and under the the in XX-K these on for

a hold session. After question-and-answer our will remarks, we

now Jim Boyd. Jim? over turn our I President the to will call and CFO,

Jim Boyd

Thank on this a Today Marrone you, joining for Bio. landmark Linda, everyone for is thank to and us you call. day

executing high-value challenging growers that long-term of support providing others First, and alternatives affected have the strategy we year’s us above agricultural record growth industry. environment. current who at second realized and This well in production focus and sustainable more enhance both revenues than by the with in our first us on their We been quarter are from the half this others differentiates rates practices.

have we technology agreement makes Farm expands proprietary announced entered which nutrient to Pro that acquire Second, we that into the a biostimulant definitive market. reach into our company, a the

expanding expanding to reach. aggressively flow in from and acquisition acceleration be the expected are global contributes path our to to accretive breakeven. to options crop is platform our health operations for XXXX protection of with We and income plant new our net This and cash and

plan, we facility and There operations. secured strategic strategic of unique cash our operational I’d information to highlighting expect commercial and we positive by to is flow a our second to financial Under like this positive will today, fund digest start Finally, needs. funding that and us opportunities of the and the quarter first lot performance half. the financing can to take have access a current cost-effectively

will Marrone. newest to on and then Pam addition touch the financing new discuss briefly I’ll the facility,

a increased XX.X% discuss you quarter to of Slide If record let’s the would quarter. X, to second for million. $X XXXX Revenues turn second the

Regalia tomatoes. crops. We to of crops in saw discussed fungal raw and specialty berries, such As Venerate revenues and into our we’ve the insect from nuts, use as second and apples in and treat crops diseases quarter previously, shift away significant specialty

BioUnite strategy. our We are driven particularly pleased with growth by the revenue

from We the of option with who harness of seeing to having strong chemistry. are the growers performance power interest biology unique the like

in about like tariff strong or our growing we, are soybeans are agriculture, with headwinds. weather growers are concerned quarter, in nationwide the facing in health farmers. second Illinois, almonds and Even California others Whether of they U.S.

Our component That diverse ability basis that we on second will inventory just-in-time through We continue portfolio crop quarter distributors one experienced strong through a to in trend seeing anticipate critical control in some of more inventory U.S. the are of and is by conditions our or rely national a a to this manage any region. adverse said, and approach. efforts XXXX. on

R&D favorable million XXX when increase same of product additional margins XX.X% legal, operating spending consulting points employee-related part compared and The mix. some and of expenses. accounting, $X.X of basis and by our were of also acquisition-related to $X.X million the in ongoing increase was other expenses. Gross innovations, million. in included in primarily plus period expenses in our XXXX field expenses toxicology a with as in trials our team expanding quarter Operating commercial because accelerating million $XX.X This function in improved investments $X of the

for a $X.X quarter million the second for the was loss of $X.X quarter of net operating expenses mentioned for previously. XXXX to second million mainly increased of was – quarter loss the XXXX Net the due compared with

capital. in used than of $X used million the working lower the because operations quarter in of improved XXXX $X.X million was Cash second XX.X% or

favorable Margins half our were production manufacturing efficiencies sales. facility. strong and at go would some and million, $XX.X from and increase benefited to to mix. as for the X, a volumes XX.X% first half I’d high through Gross first XXXX like Michigan for please Slide you If well, on XX% reached a in margins also record half reaching a first year-over-year the sales half highlights. higher turn of first Revenues product

as commercial expenses. team and million with acquisition-related As second strategic our in and accelerating line expanding to million mentioned expenses. with compared previously in remaining previously innovations XXXX to The additional other increased our $X.X I is employee-related primarily operating as R&D balance expenses legal, to our indicated first investments in well results, mentioned quarter $XX.X million half – with $XX.X due accounting

loss Net XXXX $XX.X of loss $XX.X was half per for or in a XXXX. first $X.XX per same with million or of the $X.XX the net share of period million share compared

in discussed of [Later half million a restructuring. debt quarter by Company call, benefit to changed XXXX] we of non-reoccurring the net financing our the other includes income XXXX and As to to $X.X comprehensive first first our related

XXXX. Additionally, million of with the half diluted half in the shares million first average shares the first were compared shares outstanding XXXX of XX.X XXX.X in

in used period. Cash XX.X% lower operations six year same $XX.X the of million was first or months the the $XX year in in the ago used million than

transaction to our us largest innovative of for would stock $X. have facility today. This financing by discuss as-needed by our to that price Two an providing on you demonstrated and allowing turn meets we If announced I’d Slide facility X, strategic shareholders support above needs. their at like company financing the to basis access any us to remains call time current warrants an existing future funds of our the allows exercise the

intend we and only minimizing addition, therefore funds these needed, any dilution. to when if potential access In

September. have draw from $XX issued warrant initial million XX facility, shares equates by an warrants warrant We of coming under early which million existing the our to of

financing existing under Our will current flow today’s operating our current announced this technologies is give believe under we The growth. of R&D operating and designed platforms us to leverage believe breakeven cash we additional – our Farm. and to remaining to to with and facility take acquire with acquisition unused be Pro products commercial, $XX.X million us plan, flexibility available the enough to accelerate plan, manufacturing

also strategically strategic a can example invest for through a of Farm and long-term Pro of us how gives options. immediate capacity the definitive to we warrant We enhances financial presence is that turn announcement facility Today’s to perfect larger agreement commercial long-term the growth. to in this acquire both our break believe

XXXX. be flow acquisition, there which will believe resulting expected many we and is opportunity be operations this income accretive addition, from cash to synergistic In to net from in

year Bio. XXXX announcements is Today’s short, rapidly and for transformative turning vast Marrone results potential. a into our underscore In

now would more to over review turn call strategic to acquisition of detailed this I vision. like and for Pam the a

Pam Marrone

a options with adoption a other as commercial the larger platform lead creating enhanced Pro the strategic are established and will of long-term months well of to crop Thank and we on broader plus purchase period results critical a partner Bio. a to for the we the choice as you, protection companies. X, With believe as of definitive this activity financing Marrone to We emerging point extraordinary We presence. be Farm in bio-based products. significantly on front Suffice of distributors and as Jim. XXXX announcements Slide ag six have growers with say, consider at last turning facility, been agreement today’s show every

needs Marrone Bio in today’s ag strategically with sync environment. growers’ in is

of mind. demands investment more and their practices, while point, we around Our production. achieve in that a end we goal preserving and higher is aligned pressures usefulness for them help the with transparency regulatory consumer all longevity consumers’ food greater with addressing are return and on to production believe sustainability To the

today’s leading signaling intention believe ag we we scope have achieve the industry. to goal and the capability company support company and inputs the major of financial and scale. to the announcements, of a We biological technology, be biologicals With our are agricultural our inputs creating in talent a

the revitalized revamp our in for potential, a customer The the and revenue half year financial sales relations. first the the change organization step of results reflecting of represent

conserving our solid continue are effectively deliver We managing to gross and and margins ongoing expenses cash.

include strategic us striking our access allow maintained with technologies. R&D, commercial focus select leverage These collaborations have complementary other ag R&D manufacturing to that opportunities. and our We investment and leaders on

with in to such health microorganisms Compass markets opportunity increasing new Minerals one ways and in related develop we’ve months, large us different the to Valagro. last to mine Plant our plant sustainability. with one X.X enhance products Nutrition give library Both Specifically, of collaborations, the while just in cost-effectively two announced

crop turn The further Pro growers’ Pro to technologies treatment proprietary and to business unique crop us the path potential gives would to with expand has serve our Farm agreement If needs. definitive production you X. and soil protection and biostimulant forward to and the seed a products. breadth Farm nutrient Slide acquire of

the is and major sugar Farm treatments of oilseed development. specialty in gain products. The foliar beets, global sunflowers, and our crops cereals, opportunity of corn, available seed currently as crops Pro for in major expand also a We and network with all raw distribution other the to vegetables, portfolio rape

Europe being to Haven opportunity and It product in with raw particular offering the This our is are and build Europe. Pro distribution in is in products and underway seed North America, world’s launch areas, market. CIS, expansion sold the expansion agricultural on an space. and enables our the TerraConnect biostimulant soil large of another further America, with Asia. platform Africa in strength serve commercially into the multibillion-dollar The the crop most Farm Its primarily Latin of agreements of exciting for us also

strategy. distribution Pro to have products margins We and to product product potential current average. the have offer more gross so Farm’s our extensive than global portfolio line an under higher a do significantly expanded

Slide production proprietary value operations X be and million income illustrates adjustments from plant a made by industry yields to $XX.X of converting expect Farm Pro certain Depending through improved flow XXXX. agreed net a and partial and closing, have the This to closing emergence deliver more to products plant Farm’s accretive payments transaction an starts stock Pro health. subject sales cash These be XXXX. totaling and expect to timing and by milestone patent-protected into in by-product higher process. including robust enterprise XXXX that plant we the year in would would overall earlier stimulants. on with establishment, plant is cash and encouraging pulp-and-paper from It

partner Turning forward marketplace. we for a position short, X. establish to to and options. biostimulant others juncture products turn gives and We in unique are a company’s strategic clear the transformative space us through to leverage presence technologies commercial access in break The better for financial hand and that critical a ourselves has at to Slide significant larger with commercial as in see bioprotection. is in the long-term capacity leading XXXX of path in accretion can to our poised position evolution, In growth. our now the the a We year. choice as expand emerged

billion outlook where around investment This, started, rise of strategic our we in boost an for in fruits for are assumption XXXX is the assumptions, the As accurate crop by reminded I that today demand The even in tried-and-true the with increase agricultural XX playbook. and compared the anticipate with proteins, ag protection was these different of the the and than with vegetables. X.X% was XX% growth world Bio GDP what case large is projected the future, time. to I’m well-known. hovers Yet above need and for to global demand growth expected through we market and start for back to XXXX just course, its XXXX. look agriculture in where from population by The Marrone for classic

We has stewards ever clamoring is are significantly land, predictive. tools. landscape at always Marrone faster than before historical and but precise of not income to and that peak, are great alternatives farm growers are been sustainable Bio off shifted. more they data-driven believe the Net have just cost-effective moving are its but Farmers the for

is cost-conscious but is where space produced of and and and Bio growers, affordable who for forward strategic direction. the for outsized purview is towards ours remains philosophy transparent companies these How believe no is and agricultural is for our just and progress Thankfully, trends and longer going those growth consumer exists hallmarks we This The made like food sustainable afford our more of production the can aware. Profitable leads traceability are guiding most it. being the create investors. and that food security. the can consumers, Marrone is that

we’ve Thank with you. company. our with your up call share as and We’re you strategy questions. pleased to the we would the progress like open more our We made transform about to

Operator

Up [Operator Gilson. to we’ll Research, first from Instructions] you. Investment go Zacks Thank Ian

Ian Gilson

you Hi, good all. to afternoon

at what go that growth part little impediment an has you second and cash lower line about hold the profit. through or you Could data, that G&A positive been? what number the the number a return to can showed also than how increase, in to constitutes flow significant quarter more to but it which mentioned the had you Looking to a and is of

Jim Boyd

Yes. This for is Ian, the question. speaking. Jim thanks

operating a see they’re have at at we that historically, If flat, expenses quite flat conscious very you I our maintaining look think you’ll and been them level. about

calls, [ph] and few Majestene last investment XXX mainly our team product. the Super indicated in our accelerating that and in commercial we’ve in However, also we’ve increased innovation, our our

the $X and a take field that supporting that of which by dollars. and really sales And If we’ve million couple herbicide mention out Majestene. you half take for operating from the specifically expenses, the Super that only you million trials, and legal XXX increased was acquisition-related that first increased approximately million toxicology and did are we expenses $X.X

in expenses. leaves modest that a operating very So growth

and line, think substantially few what I focus X Where get the you’ll recent you’ve we is are breakeven growing should cash our – that you the in quarters, flow top that on seen of margin our substantially breakeven. of same necessary at amount the And that to them accelerate revenue to enhancement. converging line are time, is revenue the and, to our improving us the two get

Ian Gilson

Okay.

you $X of So will number can million into look half come I as out assume that year? second that the the of

Jim Boyd

expect I would that this Jim is – again. Ian,

Ian Gilson

Yes.

Jim Boyd

would expenses those and of third that quarter. amount out you can the view occur amount a and would of expenses. come similar sort that of that, acquisition-related that, in expect after I will as onetime legal sort expect that But

Ian Gilson

much. very you Thank

Operator

go ahead. Instructions] [Operator We’ll of to Aegis. go Weinstein Please next Nathan

Nathan Weinstein

Good and afternoon, question. Pam taking thanks and my Jim, for

Pam Marrone

Hi, Nathan.,

Nathan Weinstein

guys. Hi,

firstly, the And have more get then paid secondly, pay what to a was how at generally can to perhaps line announcements, you for announcement, kind And what too into this you of in give what EBITDA insight on multiple the organization did So acquisitions or any market? plan combined of of us then if will you them… manage you like, look end you a interesting as details, any can’t sales? big quite an specific, couple may

Pam Marrone

that take I’ll Yes, first.

Nathan Weinstein

Some of the synergies might be.

Pam Marrone

it turn over Yes. Jim. to I’ll Then

international us unique that it So we will that investment cash Also, and we biostimulant our growth, our at shareholder achieve price improves big value. we’re space accelerate footprint. – think increases earlier improve a flow excited into found our a the and positive gets fair

growth, anything Jim, at think growth got before add? so right – we we’re at the transformative want it’s there’s company you is cusp we possibilities. it did where – of the So to

Jim Boyd

would because is it we answer Yes. of I’m to enhancement. that year, so in a should as margin growth what question revenue be be additive it we’re that we growth addition breaking the XXXX, I that and And our out that the will on minor. I’ll earnings is. additive and to expect sorry, think accretive. we significant out the we in that the acquisition bit And you think about acquiring little think Pro were is to results the would, expect I late question, but in think going our Farm, it our to XXXX, therefore, be already good say, you

So for it cash will a plus flow. be

Pam Marrone

the technology. this team exciting good is Now the Chief entrepreneurial an majority will [indiscernible] Farm separate able as subsidiary. to to our far Set what going do, the because acquisition going as managed a reporting it’s be and of that, up how Pro move very separate was attractive the the is Commercial and forward, about the as forward. entrepreneurs, into commercial, – of it’s going head to quickly subsidiary, have Farm, team what Linda? be – CEO market to We and being Pro to able right, subsidiary, going with therefore, like activity And a Officer, of be Kevin, been

Nathan Weinstein

Okay. Thanks.

say fair dialogue there have for it had for with them to a the known and is while So team quite a some that you’ve time?

Jim Boyd

have We’ve exhaustive and starting have on cost-effective and diligence see modeling we feel very growth done should very them. in XXXX. coming in these and the done that extensive great on from due them marketplace, very We a product good confident they guys

Nathan Weinstein

But are It’s incorporate to that and Thanks. been greater grower there then guys And biopesticides that now adopt willingness just more your you top-down a marginal out program? intended field the Okay. to past, question. as to showing talking one biopesticides in in have they are may for when me. team their growers, reticent the

Pam Marrone

go products resistance. color lot into to – market can with traditional being chemicals more is growers developing point more tipping importantly, removed ROI regulatory-wise, on products solutions. But higher combinations bioprotection and showing products. their really the of and a BioUnite at there’s we’re Kevin – pressure from give think a do being pests – on We the our strategy with growers it, the and us of a And

So they and our products, challenges add want to any adoption. a that? can more that to you growers did even with days, the these have is get some ROI better if driving really Kevin,

Kevin Hammill

the part about that, harness adoptions the this familiar talked where again, on chemistry. and was we research for grower some biology I of our of I’ll of Midwest we power just And – the BioUnite. comment some gave with looking build today treatments. is just market and fungicides Pam’s we in the people we’ve over call And at the examples also California. in looking our seed the – Yes. from previous And how And strategy not from BioUnite with performance various to about

of our higher performance damage to we week seven. earnings last they on Venerate the because most then combination last of investment, – a together. two And to our less crop of and revenue how with growers’ the prevalently, about up or This six talked the traditional less higher products combining we’re leads and and product overall protection damage it return where products see call high

weeks, seen reps from in great over our from anecdotal back particular, look perceptions terms And of this discussions one this almonds. significantly. where strategy we in concept increased market sales in year. grower almonds showed whole I in concept of and, uptake. then BioUnite they’ve to the last That So at great started in this this the market adoption research, the the research with Then few

Nathan Weinstein

guys. Okay. Thanks a lot

Operator

Center Performance Smith for Investing. go ahead. Robert to Please of next go We’ll

Robert Smith

and is good market. provide will entrée the that EU, ban that Thanks glyphosate wondering within an Hi, into whether acquisition Austria to my questions. I’ve afternoon. for the read I’m trying

Pam Marrone

herbicide and the has biostimulant, products, market. Pro Farm not in bionutrient they’re

to? don’t I But think do Kevin, so. want So you

Kevin Hammill

of our products is herbicide could Pam, over been build on for just the the we that. And developing market, a that think, cheerleader has that Pam one I that fit great new our XXX And years. this we’re in is that Yes, have. partner, product

Pam Marrone

Yes.

Kevin Hammill

forward and footprint, maybe going European our a a is look one into to XXX How a them excited we that forward, So help bringing bring have new but in solution solution, could needs that the of options. is the not would to Farm that we’re Austria extremely they grower. use footprint the specifically to those in if We market. herbicide Pro XXX us grower Europe,

Robert Smith

I what of that’s I Actually, Yes. was getting XXX. mention sort didn’t at.

through last updates some that us So Pam, you current Just product of view. give us could months portfolio give them the you us as the as – take spoke and time? a to three

Pam Marrone

and market, treatment we’ve we’ve year the as moved press the in the products, first and the seed to in Venerate Well, strong as usage continue mentioned specialty – half crop releases third three we the second leading all move Regalia, in quarter. Grandevo, and we’ve and will such, quarter back And and first to Regalia seen crops Venerate – the in well, of the various growth to of from fourth treatment the quarter. specialty quarter then the in seed and of

to exciting just we one – hence, we products. what’s imminent. but of – webinar. me did we approval product with traction growers we And the some our and is California, awaiting it’s started getting of it’s So a And that our is for in still Stargus hope And marketplace. have customers. webinar most the Stargus recent

I’m strong And well, – season it’ll hoping white greens. downy the excited product and mildews. to in controlling downy along strong be leafy – mildews moving there fall we’re as molds a for especially that our is for see next a So

the of nice formulations compared looking that to compared in at one developing. data very field. one looking it believe very exciting, our Majestene at the and Now will growers new cost I is multiple saw this investing trials various have the product, field, why called very now have which of which right to high-growth looking exciting. increase we we’re we’re the the which field formulations, down and really we in and potentially And is in it. a formulation project driving out potency, Super – transformative we’re and just XXX, XXX sorry, some investing a to we in in which hence, XXX, versions And is making herbicides, main the it glufosinate,

well. I I’m we’ve as the sorry, – got think So pipeline and

a You second Ennoble growers also in might one the approval biofumigant, and improved got Ennoble, and time with our have we’re second did for waiting and, a remembered of California significant yield the there. or row, – demo leading a a strawberry with leading

Robert Smith

And update on any Zequanox?

Pam Marrone

ask Oh, exciting actually. Yes, of to knew very I a going update that. yes, course. you were

So with yesterday, presence the Lake team, lake, partners, the group impact along because mussel in the control area algae, algae whole that Harbor to the a our of reduce treatment the of trying to there. causes increases toxic Leland/Good toxic Michigan mussel the we did a mussels

excited another prospect. power maintenance as addition, very going or into to this we’re And preventative by with plants. treatments we one, future plants, some week in do – large Canadian another our this as in some well treatment and we’re going we’re So into a treatment power

industrial with to that future to the objective and product. the drive for how the – can to in facilities in and power revenue we – the the really So plant see provide value customer

Robert Smith

begin demo to commercial some you more to would need product? many get for how the projects orders So

Pam Marrone

pipe – In do pay industrial are are the – correct if the the product. Kevin, They wrong. for. paid I’m So for purchased. me and all treatment They’re all

Kevin Hammill

Yes.

Pam Marrone

Yes.

the So for product. in they do the of Lakes, the pay treatment Great

to so they’re Michigan in demo the yes, where in so – you demo trying we’re is the the might we’re in ways trying excited so we’re doing while product mussels Lake about site feed. – And – a keep – another

year. And trying methodologies application so they’re different this some

the that, by excited potential we’re said, yes. I of as So

Robert Smith

we registered? the as in that far getting mean where now process of goes, XXX as And I are

Pam Marrone

the is and product and focus but I water position – agency, the to to And formulations large team meanwhile, those key really along predict not as taking to in that we’ve – doing we hemp way that’s get launch, palmer got all the doing the not winding always exciting. And amaranths, its through. on it’s and is things it multiple R&D and proud to doing the yes. are – Well, invest mentioned, and weeds herbicide-resistant we’re we markets real happen, when going the can doing development when to everything – killing

Robert Smith

I’m wondering, recent the in I’m made reflected is of going, this past. reducing And your how past, being the profile progress wondering Yes. products? it the is some cost and how in substantial You’ve

Pam Marrone

Yes.

a we’ve at look evidence. – going if I how prototypes So say say about the a on with the look it’s some lumpiness of to touch-base And last although Majestene week did due compounds excited efficiencies R&D. team mix, would a efforts products all gone – and we’re for progress, Super the Kevin, We the you big XX-something that we to had just to XXs good. the meeting that now. there the the activity. past we’re improvement get dramatic But project? to evidence pest-killing Majestene due from product but a that – you in to that of showing the nematode-killing – caused early that want Super our that’s continued anything And beautiful to the is there’s quarters the lot up year margins, been it’s last both gross from that manufacturing really

Kevin Hammill

one. a but really running Yes. yes. positive transform joke this on That I’m has company. here, bit of become It’ll a Well, the

Pam Marrone

have XXX. I

You have Super Majestene.

Kevin Hammill

Exactly.

pest management, out positive there. we’ll for where have meeting formulation insight will made we’re coming last from review global to part integrate the that great back both with registration. Majestene advancement bioassays from Friday, this The we programs chemistry So of the just field building on and mentioned strategy multiple the that we product positive the looking forward some away year. BioUnite lab And progress aggressively this came are and whole our trials Pam our into from be Super formulations

into low-usage, to product excited high-performing fit marketplace. how we’re can really So this the

Robert Smith

those mean, would be to that process, to cost profile reduce it this I costs? fair So continuing say will in be work a

Pam Marrone

continue. will we Yes,

continuously. or So processes tweak knowing continue as do, microbes change I you to can

topping an and microbes able with be start biology Majestene reduce you these technology the power but project. we’re genomics seeing of days, costs. Now and out amp the to – in in up got more modern initial that bump-up. Super where to these to And tools you’ve there’s now molecular And our

Kevin Hammill

so a think rate further. the this Yes. go great actually integrated become our it’ll down for Kevin the again. the for – they in-furrow parts me, of product that usage And one to really is getting down cultural excitement as is fit got I’m to lower for And programs a this and more grower, We now. it’s forward going level, practices even that into we their –

as improve forward the get and phenomenal think we’ll forward. product decreasing a formulation, going I go the we rates,

Robert Smith

you going effort far itself marketed. I goes, the last promote the quarters, the as acquisition, the is itself? mean effort to aside to the are products put this in And essentially that as with R&D really being R&D But the focus few revitalize just

Pam Marrone

have we will – have I’ll mention Valagro. two today, Well, collaborations we mentioned and Compass that – Minerals I we that

microbes So other early-stage further into our current biostimulant plant commercial the our that to enter nutrition the and pipeline outside products of market. mines of into

if Kevin, – you that that’s some pipeline what products to Farm additional revitalization, the already to assets and monetize see Pro of So call leveraging have. to R&D as helping And you as we far I’ll it is then, an the and or you over turn the there.

Kevin Hammill

Yes.

foliar or putting Just Pro we our – the see we only that on, off, Davis. we team by development as the generation of and still accelerate such yield products see And with increased facilities Venerate Farm and MBI can world-class technology there’s technology. we products, in Not even building next can our first two standpoint, Majestene whereby the our synergy and products quality Farm a together. believe has that, research the help Pro or

further the development, standpoint, penetration products to increase also, and from traditional commercial we synergies access, both the BioUnite And But market. this with our with their with here portfolio to their products ability see market two see chemistry research a also and – our the facilities will and world-class be a we enhance strategies between companies. so market grow from

Jim Boyd

I efforts and dollars to while all majority commercial Majestene, I’d of a – announce. you’re Jim. namely XXX investment probably add, substantial and our time is these on products, this that just existing R&D is there collaborative us a just seeing like in are spent very Super pipeline, and still

Pam Marrone

Yes.

Robert Smith

so much the Thank for That you sounds encouraging. luck. Good color.

Pam Marrone

you. Thank

Operator

management. time, at the to further no with turn And questions to back would call over like this I

Pam Marrone

company, our has to global and Thank your us to platform been strategic joining we’re our excited you and Bio. biologicals accelerate a our company day growth the pursue a landmark by large, again create to for possibility further in for objective Marrone today This and potential. interest for

close lot of work We operation. we transaction Farm the us of Pro them into our and a as ahead integrate have

do a the we future of to forward of Innovations. value about Marrone further Thank way for process. Bio and shareholder with look create agriculture Again, confident We captures can speaking new in significant And the are we thanks. that you. the future a you our so potential in

Marrone Bio Innovations (MBII) 10 Aug 192019 Q2 Earnings call transcript